M&A / Deals Servier wagers $2.65bn on Edgewise muscular dystrophy drug PharmaphorumServier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.Rare DiseaseRead full story pharminent June 1, 2026 (Last updated: June 1, 2026) Pharmaphorum Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise’s muscular dystrophy business headed by sevasemten. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO: Summit reached with China lung data but new climb begins to prove global benefitNext: CordenPharma inks AmbioPharm buyout to continue peptide production expansion Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
